LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Cardiac Implantable Electronic Devices and Consumer Electronic Devices: The Proof Is in the Front Pocket.

    Ellis, Christopher R / King, Nicholas E

    The Journal of innovations in cardiac rhythm management

    2022  Volume 13, Issue 7, Page(s) 5073–5076

    Language English
    Publishing date 2022-07-15
    Publishing country United States
    Document type Journal Article
    ISSN 2156-3977
    ISSN 2156-3977
    DOI 10.19102/icrm.2022.130706
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

    King, Nicholas E / Brittain, Evan

    Pulmonary circulation

    2022  Volume 12, Issue 1, Page(s) e12028

    Abstract: Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH-LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines of ... ...

    Abstract Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH-LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines of experimental evidence link metabolic dysfunction to the pathogenesis and outcomes in PH-LHD and PAH, and novel metabolic agents hold promise to improve outcomes in these populations. The antidiabetic sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) agonists targeting metabolic dysfunction and improve outcomes in patients with LHD but have not been tested specifically in patients with PH. The angiotensin receptor/neprilysin inhibitors (ARNIs) produce significant improvements in cardiac hemodynamics and may improve metabolic dysfunction that could benefit the pulmonary circulation and right ventricle function. On the basis of promising preclinical work with these medications and clinical rationale, we explore the potential of SGLT2 inhibitors, GLP1 agonists, and ARNIs as therapies for both PH-LHD and PAH.
    Language English
    Publishing date 2022-01-18
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2638089-4
    ISSN 2045-8940 ; 2045-8932
    ISSN (online) 2045-8940
    ISSN 2045-8932
    DOI 10.1002/pul2.12028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: It all started with a clubfoot: Beliefs surrounding cerebral palsy throughout history.

    Stang, Kristina M / King, Nicholas E / Gaebler-Spira, Deborah

    Journal of pediatric rehabilitation medicine

    2019  Volume 12, Issue 2, Page(s) 115–121

    MeSH term(s) Biomedical Research/history ; Cerebral Palsy/diagnosis ; Cerebral Palsy/history ; Cerebral Palsy/therapy ; Egypt, Ancient ; Europe ; History, 19th Century ; History, 20th Century ; History, 21st Century ; History, Ancient ; Humans ; United States
    Language English
    Publishing date 2019-07-08
    Publishing country Netherlands
    Document type Historical Article ; Journal Article
    ZDB-ID 2403637-7
    ISSN 1875-8894 ; 1874-5393
    ISSN (online) 1875-8894
    ISSN 1874-5393
    DOI 10.3233/PRM-190005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Two iPSC lines generated from the bone marrow of a relapsed/refractory AML patient display normal karyotypes and myeloid differentiation potential.

    Yamasaki, Amanda E / King, Nicholas E / Matsui, Hiroko / Jepsen, Kristen / Panopoulos, Athanasia D

    Stem cell research

    2019  Volume 41, Page(s) 101587

    Abstract: Using iPSCs to study cancer has been complicated by the fact that many cancer cells are difficult to reprogram, which has been attributed to the genomic abnormalities present. Acute Myeloid Leukemia (AML) is a complex disease that presents with various ... ...

    Abstract Using iPSCs to study cancer has been complicated by the fact that many cancer cells are difficult to reprogram, which has been attributed to the genomic abnormalities present. Acute Myeloid Leukemia (AML) is a complex disease that presents with various types of genomic aberrations that affect prognosis. Here we reprogrammed CD34+ cells from an AML patient containing a rare der(7)t(7;13) translocation associated with poor prognosis, who had relapsed and was refractory to current treatments. The generated AML-iPSCs displayed normal karyotypes and myeloid differentiation potential. These findings have implications for modeling and treating AML disease.
    MeSH term(s) Aged ; Bone Marrow/pathology ; Cell Differentiation ; Drug Resistance, Neoplasm ; Humans ; Induced Pluripotent Stem Cells/pathology ; Karyotype ; Leukemia, Myeloid, Acute/pathology ; Male ; Myeloid Cells/pathology ; Neoplasm Recurrence, Local/pathology ; Tumor Cells, Cultured
    Language English
    Publishing date 2019-10-17
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 1876-7753
    ISSN (online) 1876-7753
    DOI 10.1016/j.scr.2019.101587
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.

    King, Nicholas E / Suzuki, Shingo / Barillà, Cristina / Hawkins, Finn J / Randell, Scott H / Reynolds, Susan D / Stripp, Barry R / Davis, Brian R

    Human gene therapy

    2020  Volume 31, Issue 17-18, Page(s) 956–972

    Abstract: Cystic fibrosis (CF) is an autosomal recessive disease caused by variations in the cystic fibrosis transmembrane conductance regulator ( ...

    Abstract Cystic fibrosis (CF) is an autosomal recessive disease caused by variations in the cystic fibrosis transmembrane conductance regulator (
    MeSH term(s) Cystic Fibrosis/genetics ; Cystic Fibrosis/metabolism ; Cystic Fibrosis/therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Gene Editing/methods ; Humans ; Respiratory Mucosa/cytology ; Respiratory Mucosa/metabolism ; Stem Cell Transplantation/methods ; Stem Cells/cytology ; Stem Cells/metabolism
    Chemical Substances CFTR protein, human ; Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6)
    Language English
    Publishing date 2020-09-08
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1028152-6
    ISSN 1557-7422 ; 1043-0342
    ISSN (online) 1557-7422
    ISSN 1043-0342
    DOI 10.1089/hum.2020.160
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top